teicoplanin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
glycopeptide antibacterials (Actinoplanes strains) 2998 61036-62-2

Description:

MoleculeDescription

Synonyms:

  • teicoplanin
  • Antibiotic 8327A
  • Antibiotic MDL 507
  • targocid
  • targosid
  • teichomycin
Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety.
  • Molecular weight:
  • Formula: None
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.40 g P

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 205.14 32.23 78 3744 28346 50572956
Thrombocytopenia 82.91 32.23 72 3750 127601 50473701
Acinetobacter infection 74.28 32.23 18 3804 1409 50599893
Stenotrophomonas infection 66.54 32.23 17 3805 1652 50599650
Pyrexia 63.28 32.23 107 3715 380096 50221206
Multiple organ dysfunction syndrome 62.89 32.23 42 3780 50295 50551007
Anaphylactic reaction 62.52 32.23 43 3779 54012 50547290
Septic shock 60.34 32.23 43 3779 57132 50544170
Drug resistance 56.73 32.23 28 3794 18961 50582341
Neutropenia 55.75 32.23 62 3760 147903 50453399
Enterococcal infection 49.90 32.23 19 3803 6879 50594423
Mental status changes postoperative 49.33 32.23 9 3813 174 50601128
Acute generalised exanthematous pustulosis 48.50 32.23 20 3802 8918 50592384
Confusion postoperative 48.40 32.23 9 3813 194 50601108
Haemodynamic instability 47.11 32.23 19 3803 8005 50593297
Cross sensitivity reaction 45.29 32.23 13 3809 1956 50599346
Morganella infection 44.28 32.23 10 3812 575 50600727
Rash maculo-papular 42.62 32.23 26 3796 26615 50574687
Pathogen resistance 42.34 32.23 16 3806 5673 50595629
Haemostasis 40.52 32.23 8 3814 239 50601063
Eosinophilia 39.93 32.23 22 3800 18630 50582672
Renal impairment 37.96 32.23 37 3785 75624 50525678
Bronchopulmonary aspergillosis 37.87 32.23 16 3806 7576 50593726
Klebsiella infection 35.34 32.23 15 3807 7179 50594123
Sepsis 34.23 32.23 46 3776 132879 50468423
Rash macular 33.90 32.23 20 3802 19257 50582045
Folate deficiency 32.32 32.23 10 3812 1945 50599357

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 126.35 26.38 69 4539 27923 29541996
Pyrexia 93.83 26.38 163 4445 287459 29282460
Cross sensitivity reaction 91.57 26.38 24 4584 1238 29568681
Venoocclusive disease 74.99 26.38 24 4584 2515 29567404
Rash maculo-papular 60.63 26.38 41 4567 24248 29545671
Multiple organ dysfunction syndrome 56.81 26.38 59 4549 63057 29506862
Thrombocytopenia 51.09 26.38 82 4526 134741 29435178
Neutropenia 49.75 26.38 80 4528 131631 29438288
Systemic candida 49.55 26.38 18 4590 2762 29567157
Hyphaema 48.83 26.38 12 4596 476 29569443
Eosinophilia 45.04 26.38 33 4575 22128 29547791
Septic shock 45.00 26.38 52 4556 62508 29507411
Systemic mycosis 37.01 26.38 12 4596 1309 29568610
Fatigue 35.54 26.38 4 4604 316817 29253102
Drug resistance 34.82 26.38 28 4580 21512 29548407
Stevens-Johnson syndrome 34.50 26.38 25 4583 16472 29553447
Acute kidney injury 32.80 26.38 103 4505 265164 29304755
Thrombotic microangiopathy 32.59 26.38 19 4589 8662 29561257
Geotrichum infection 30.06 26.38 8 4600 437 29569482
Coagulation time prolonged 29.91 26.38 10 4598 1200 29568719
Haemophagocytic lymphohistiocytosis 29.25 26.38 19 4589 10485 29559434
C-reactive protein increased 28.83 26.38 35 4573 44228 29525691
Renal impairment 28.73 26.38 48 4560 81285 29488634
Cytomegalovirus infection 27.00 26.38 25 4583 23190 29546729

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 300.34 23.58 145 8320 54072 64436195
Pyrexia 151.03 23.58 265 8200 558379 63931888
Thrombocytopenia 129.79 23.58 153 8312 223648 64266619
Cross sensitivity reaction 127.34 23.58 37 8428 3330 64486937
Multiple organ dysfunction syndrome 105.42 23.58 95 8370 101318 64388949
Neutropenia 104.24 23.58 142 8323 239482 64250785
Septic shock 100.31 23.58 94 8371 105343 64384924
Rash maculo-papular 99.17 23.58 67 8398 46959 64443308
Acinetobacter infection 88.79 23.58 26 8439 2403 64487864
Anaphylactic reaction 86.87 23.58 72 8393 68592 64421675
Eosinophilia 82.06 23.58 55 8410 38021 64452246
Stenotrophomonas infection 74.45 23.58 24 8441 3056 64487211
Drug resistance 73.95 23.58 50 8415 35052 64455215
Venoocclusive disease 72.24 23.58 25 8440 3960 64486307
Enterococcal infection 58.76 23.58 31 8434 13835 64476432
Fatigue 51.83 23.58 17 8448 748713 63741554
Geotrichum infection 47.99 23.58 13 8452 905 64489362
Sepsis 47.76 23.58 98 8367 230243 64260024
Systemic mycosis 47.69 23.58 16 8449 2307 64487960
Hyphaema 47.36 23.58 12 8453 643 64489624
Renal impairment 46.84 23.58 72 8393 134945 64355322
Acute kidney injury 44.88 23.58 145 8320 449095 64041172
Fungaemia 43.57 23.58 17 8448 3768 64486499
Stevens-Johnson syndrome 43.45 23.58 36 8429 34213 64456054
Toxic skin eruption 41.87 23.58 28 8437 19256 64471011
Pancytopenia 39.65 23.58 69 8396 143240 64347027
Mental status changes postoperative 39.27 23.58 8 8457 158 64490109
C-reactive protein increased 39.25 23.58 55 8410 94854 64395413
Off label use 38.99 23.58 175 8290 632631 63857636
Confusion postoperative 37.55 23.58 8 8457 198 64490069
Acute generalised exanthematous pustulosis 36.90 23.58 23 8442 14035 64476232
Febrile neutropenia 36.72 23.58 78 8387 187579 64302688
Fall 35.59 23.58 6 8459 416820 64073447
Klebsiella infection 35.55 23.58 22 8443 13259 64477008
Haemostasis 35.16 23.58 8 8457 270 64489997
Cholestasis 35.12 23.58 36 8429 44836 64445431
Toxic epidermal necrolysis 35.02 23.58 33 8432 37133 64453134
Morganella infection 33.41 23.58 10 8455 996 64489271
Haemodynamic instability 33.21 23.58 22 8443 14890 64475377
Dizziness 32.96 23.58 8 8457 430155 64060112
Haemophagocytic lymphohistiocytosis 32.19 23.58 23 8442 17586 64472681
Systemic candida 31.70 23.58 15 8450 5314 64484953
Pathogen resistance 31.61 23.58 20 8445 12523 64477744
Pain 29.71 23.58 18 8447 553493 63936774
Thrombotic microangiopathy 28.72 23.58 21 8444 16634 64473633
Fungal infection 27.75 23.58 28 8437 34223 64456044
Mast cell degranulation present 26.65 23.58 5 8460 63 64490204
Staphylococcal infection 26.55 23.58 33 8432 50645 64439622
Coagulation time prolonged 25.98 23.58 10 8455 2136 64488131
Dyspnoea 25.85 23.58 34 8431 718640 63771627
Cytomegalovirus infection 25.82 23.58 28 8437 37171 64453096
Flavobacterium infection 24.88 23.58 5 8460 92 64490175
Pain in extremity 24.48 23.58 5 8460 303080 64187187
Rash erythematous 24.41 23.58 31 8434 48602 64441665
Bronchopulmonary aspergillosis 24.07 23.58 20 8445 19065 64471202

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XA02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Glycopeptide antibacterials
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:36047 antibacterial drugs
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Staphylococcal infectious disease indication 56038003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4025272 VUID
N0000171799 NUI
D02142 KEGG_DRUG
4025272 VANDF
C0145106 UMLSCUI
CHEBI:29687 CHEBI
CHEMBL4297166 ChEMBL_ID
CHEMBL2367892 ChEMBL_ID
D017334 MESH_DESCRIPTOR_UI
DB06149 DRUGBANK_ID
10924 IUPHAR_LIGAND_ID
5155 INN_ID
4U3D3YY81M UNII
133065662 PUBCHEM_CID
196469 RXNORM
003765 NDDF
387529008 SNOMEDCT_US
96014005 SNOMEDCT_US

Pharmaceutical products:

None